Radiation Injury – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Radiation Injury – Pipeline Review, H1 2018’, provides an overview of the Radiation Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Radiation Injury

– The report reviews pipeline therapeutics for Radiation Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Radiation Injury therapeutics and enlists all their major and minor projects

– The report assesses Radiation Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Radiation Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Radiation Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Radiation Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

FirstString Research Inc

PharmaIN Corp

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

Windtree Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Radiation Injury Overview

Radiation Injury Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiation Injury Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiation Injury Companies Involved in Therapeutics Development

FirstString Research Inc

PharmaIN Corp

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

Windtree Therapeutics Inc

Radiation Injury Drug Profiles

Aerosurf Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-2E2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-2E5 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Des-Asp Angiotensin 1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DG-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSJ-0017 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate FGF-4 for Radiation Injury Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate FGF-7 for Radiation Injury Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Prostate Cancer, Asthma and Radiation Injury Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYGN-305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNX-701 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Radiation Injury Dormant Projects

Radiation Injury Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Table 1: Number of Products under Development for Radiation Injury, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Universities/Institutes, H1 2018

Table 4: Products under Development by Companies, H1 2018

Table 5: Products under Development by Universities/Institutes, H1 2018

Table 6: Number of Products by Stage and Target, H1 2018

Table 7: Number of Products by Stage and Mechanism of Action, H1 2018

Table 8: Number of Products by Stage and Route of Administration, H1 2018

Table 9: Number of Products by Stage and Molecule Type, H1 2018

Table 10: Radiation Injury Pipeline by FirstString Research Inc, H1 2018

Table 11: Radiation Injury Pipeline by PharmaIN Corp, H1 2018

Table 12: Radiation Injury Pipeline by Synedgen Inc, H1 2018

Table 13: Radiation Injury Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018

Table 14: Radiation Injury Pipeline by Windtree Therapeutics Inc, H1 2018

Table 15: Radiation Injury Dormant Projects, H1 2018

Table 16: Radiation Injury Discontinued Products, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Radiation Injury, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products by Targets, H1 2018

Figure 4: Number of Products by Stage and Targets, H1 2018

Figure 5: Number of Products by Mechanism of Actions, H1 2018

Figure 6: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 7: Number of Products by Routes of Administration, H1 2018

Figure 8: Number of Products by Stage and Routes of Administration, H1 2018

Figure 9: Number of Products by Molecule Types, H1 2018

Figure 10: Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports